What is a Hereditary Cancer Panel?
Helping Pharma companies develop Precision medicine using Clinical Data & AI.
What is a Hereditary Cancer Panel?
GeneHealth’s Hereditary Cancer Panel is a comprehensive genetic test that identifies inherited mutations in genes associated with an increased cancer risk. Using advanced NGS methods, this test analyzes multiple high-penetrance and moderate-risk genes such as BRCA1, BRCA2, MLH1, MSH2, TP53, and others. It enables early detection, personalized risk management, and informed decisions on surveillance or preventive interventions. It is especially vital when there is a strong family history or multiple cancer types present in the family.
Book a Test Now →Testing Indications for Hereditary Cancer
Clinical Benefits of Testing
- Enables risk estimation for secondary cancers and potential relapse.
- Supports personal and familial risk assessment for inherited cancer syndromes.
- Allows for early detection, significantly improving clinical outcomes and survival rates.
- Facilitates active risk management and disease prevention through tailored surveillance and prophylactic surgeries.
- Determines eligibility for targeted treatments like PARP inhibitors (PARPi) and platinum-based therapies for personalized treatment planning.
Assay Specifications
Key Highlights of GeneHealth’s Panel
Accurately identifies SNVs, InDels, and CNVs (Copy Number Variations) for comprehensive and reliable mutation analysis.
Covers the entire coding regions of target genes, ensuring no crucial data is missed by solely relying on common mutation hotspots.
Goes beyond standard testing by successfully reporting clinically relevant variants found in regulatory and deep intronic genomic regions.
